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Introduction
Trichomoniasis is the most common sexually transmitted
infection of the urogenital tract predisposing to HIV infec-
tion and cervical cancer in women. The development of
resistance against metronidazole (MTZ, the only effective
approved drug for trichomoniasis), thrown a challenge to
find out alternate medication.
Objectives
To Design and synthesize novel agents to be effective
against MTZ resistant trichomoniasis.
Methods
Benzenepropanamines and selective serotonin reuptake
inhibitor (SSRI) antidepressants viz. fluoxetine and paroxe-
tine, possibly interacting with sulfhydryl groups present
over Trichomonas.[1] Alongside dithiocarbamate nucleus
is a well established pharmacophore possessing anti-
Trichomonas activity.[2] In our ongoing efforts a series of
benzenepropanamine-dithiocarbamate hybrids (14-28) as
N-alkyl/aralkyl-4-(3-substituted-3-phenylpropyl)pipera-
zine-1-carbodithioates have been designed, synthesized
and evaluated for their anti-Trichomonas activity profile to
be useful as vaginal microbicide. All compounds were
tested for safety through cytotoxic assay against human




zine-1-carbodithioate (Compound 17) was the most
promising compound with anti–Trichomonas activity
(MIC, 39.79 µM against MTZ susceptible and MIC,
79.92 µM against resistant strain) in comparison to
MTZ (MIC, 19.71 µM against MTZ susceptible and
MIC, 292.80 µM against resistant strain). Six com-
pounds (14, 15, 17, 19, 21, 22, MIC 79.92–178.57 µM)
were more active against resistant strain in comparison
to Metronidazole. The extreme safety profile against
vaginal epithelium (HeLa cells) and compatibility with
vaginal flora (lactobacillus) supported its suitability for
vaginal application.
Conclusion
A novel molecule to be effective against resistant Tricho-
moniasis in comparison to MTZ has been identified to be
developed for topical application emphasizing on improve-
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